Smith & Nephew PLC (SNN)
|Net Income (ttm)||448.00M|
|Trading Day||March 5|
|Day's Range||37.85 - 38.26|
|52-Week Range||25.52 - 46.10|
Medical device maker Smith & Nephew plc (NYSE: SNN) slips in the premarket after reporting a slump in revenues and profits. Full-year 2020 revenue fell 11.2% Y/Y to $4.6 billion, and operating...
Smith & Nephew PLC (LON:SN) saw its shares slide in early deals as it caught the market on the hop with a disappointing set of results. Shares in the wound care and knee & hip implants special...
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System again shown to significantly reduce surgical site complications
LONDON, Jan. 27, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negativ...
The rally in 2020 may mean many stocks are not cheap any more, but long-term investors can still find robust stocks to buy in a bull market The post 7 Stocks to Buy for a Continued Run with th...
Let's see if Smith & Nephew plc (SNN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Smith & Nephew has a solid, growing business which will grow with market growth as well as by acquisition. It has a decent dividend payment history.
These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election. The post 7 Healthcare Stocks That Can Survive Massive Re...
Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q3 2020 Results - Earnings Call Transcript
In an announcement on Thursday, Smith & Nephew plc (LON: SN) said its underlying revenue is expected to see a 4% decline in the fiscal third quarter. Underlying revenue does not account for no...
Smith & Nephew SNN, +2.16% SN, -0.91% said it's buying the extremity orthopedics unit of Integra LifeSciences IART, ...
LONDON, Sept. 2, 2020 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its NOVOSTITCH PRO Meniscal Repair System in Europe...
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q2 2020 Results - Earnings Call Transcript
The pandemic hit Zimmer, Smith+Nephew, and Stryker hard -- but they'll soon rise again.
Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.
Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2019 Results - Earnings Call Transcript
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
Its chief executive's sudden exit sent the stock reeling.
Smith & Nephew PLC (SNN) Management on Q3 2019 Results - Earnings Call Transcript
Smith+Nephew Plc Chief Executive Namal Nawana is stepping down after just 17 months in the role after becoming dissatisfied with his salary at the medical device maker.
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
Smith & Nephew (SNN) has been gaining from several positive developments of late.
Smith & Nephew PLC (SNN) CEO Namal Nawana on Q2 2019 Results - Earnings Call Transcript
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Smith & Nephew PLC (SNN) CEO Namal Nawana on Q1 2019 Results - Earnings Call Transcript
Smith & Nephew has been gaining investor confidence on consistently positive results.
On March 12, 2019, Osiris Therapeutics disclosed that Smith & Nephew agreed to acquire the company for $660 million.
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive ... [Read more...]
|IPO Date |
Nov 16, 1999
|Stock Exchange |
|Ticker Symbol |
In 2020, Smith & Nephew's revenue was $4.56 billion, a decrease of -11.25% compared to the previous year's $5.14 billion. Earnings were $448.00 million, a decrease of -25.33%.
According to 4 analysts, the average rating for Smith & Nephew stock is "Buy." The 12-month stock price forecast is 49.50, which is an increase of 30.76% from the latest price.